Breakthrough Therapies - ALK with Dr. Ignatius Ou


In this episode of Lung Cancer Considered, Dr. Sai-Hong Ignatius Ou shares his career growth and experience participating and leading breakthrough clinical trials on therapies to treat ALK positive patients with lung cancer. Dr. Ou discusses a pivotal moment at the beginning of his career when he visited the Pfizer campus in California to learn about their effort to develop a phase 1 trial examining MET amplifications and MET mutations. The visit helped spur him to become more involved in lung cancer research.

Narjust Duma
Narjust Florez


Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School

Other Podcast